Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SELL | P14151 | 2/20 | 0.50 |
| ▸ | SELP | P16109 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SELE | P16581 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203188 | 0.85 | ALDH1A1 (0.54) | MAPK1GAAALDH1A1MEN1KMT2A | |
| SCHEMBL14162064 | 0.82 | MEN1 (0.50) | CASRMAPK1GAAALDH1A1MEN1 | |
| SCHEMBL10363556 | 0.82 | TP53 (0.52) | MAPK1GAAALDH1A1MEN1KMT2A | |
| SCHEMBL22753421 | 0.81 | KDM5A (0.51) | MAPK1GAAMEN1KMT2AMAPT | |
| SCHEMBL11693008 | 0.81 | MAPT (0.55) | MAPK1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4015430 | 0.79 | MAPK1 (0.50) | CASRMAPK1GAAALDH1A1MEN1 | |
| Toluene SCHEMBL11581664 | 0.79 | BRD4 (0.55) | MAPK1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL560143 | 0.78 | L3MBTL1 (0.57) | CASRMAPK1GAAALDH1A1MEN1 | |
| SCHEMBL25306345 | 0.77 | EPHX2 (0.51) | CASRMAPK1GAAALDH1A1MEN1 | |
| SCHEMBL25306348 | 0.77 | EPHX2 (0.51) | CASRMAPK1GAAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2008075064-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF OBESITY | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | GPR119, FABP4, FASN | CASR 4044/4885MAPK1 269/4885GAA 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.